Hypertension, Angiotensin, and Stroke: Beyond Blood Pressure

Stroke

Volumn 35, Issue 2, 2004, Pages 348-350

  Iadecola, Costantino ^a   Gorelick, Philip B ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Advances in Stroke; Angiotensins; Hypertension; Stroke

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; G PROTEIN COUPLED RECEPTOR; INDAPAMIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN INHIBITOR; PROTEIN KINASE C; RAMIPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCAVENGER; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; BRAIN CIRCULATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TARGETING; DRUG UTILIZATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HYPERTENSION; NONHUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SHORT SURVEY; SIGNAL TRANSDUCTION; STROKE; VASCULAR ENDOTHELIUM;

EID: 0842310817     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000115162.16321.AA     Document Type: Short Survey

References (26)

1. Wolf PA. Hypertension. In: Norris J, Hachinski VC, eds. Stroke Prevention. New York: Oxford University Press; 2001:93-105.
2. Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol. 2002;1:149-156.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
4. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363-2369.
5. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-872.
6. MacMahon S. Blood pressure and the risk of cardiovascular disease. N Engl J Med. 2000;342:50-52.
7. Chillon JM, Baumbach GL. Autoregulation: arterial and intracranial pressure. In: Edvinsson L, Krause DN, eds. Cerebral Blood Flow and Metabolism. Philadelphia: Lippincott Williams & Wilkins; 2002:395-412.
8. Ferrario CM. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens. 2002;15:9S-13S
9. Faraci FM, Heistad DD. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol Rev. 1998;78:53-97.
10. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2003;284:R893-R912.
11. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52:639-672.
12. Baumbach GL, Sigmund CD, Faraci FM. Cerebral arteriolar structure in mice overexpressing human renin and angiotensinogen. Hypertension. 2003;41:50-55.
13. Chillon JM, Baumbach GL. Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arteriolar dilatation in hypertensive rats. Hypertension. 2001;37:1388-1393.
14. Didion SP, Faraci FM. Angiotensin II produces superoxide-mediated impairment of endothelial function in cerebral arterioles. Stroke. 2003;34:2038-2042.
15. Saavedra JM, Nishimura Y. Angiotensin and cerebral blood flow. Cell Mol Neurobiol. 1999;19:553-573.
16. Kazama K, Wang G, Frys K, Anrather J, Iadecola C. Angiotensin II attenuates functional hyperemia in the mouse somatosensory cortex. Am J Physiol Heart Circ Physiol. 2003;285:H1890-H1899.
17. Attwell D, ladecola C. The neural basis of functional brain imaging signals. Trends Neurosci. 2002;25:621-625.
18. Yan C, Kim D, Aizawa T, Berk BC. Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscler Thromb Vasc Biol. 2003;23:26-36.
19. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471-478.
20. Kazama K, Anrather J, Wang G, Frys K, Iadecola C. Angiotensin II alters neurovascular coupling via production of reactive oxygen species. J Cereb Blood Flow Metab. 2003;23(suppl 1):83. Abstract.
21. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
22. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
23. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
24. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
25. Messerli FH. ALLHAT, or the soft science of the secondary end point. Ann Intern Med. 2003;139:777-780.
26. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.